Relatlimab/Nivolumab Achieves Clinically Meaningful Improvement in OS for Advanced Melanoma

 Source: Targeted Oncology, March 2022

Relatlimab plus nivolumab (Opdivo) demonstrated a 22% reduction in risk of progression or death and numerically improved overall survival (OS) rates compared to nivolumab alone. However, statistical significance was not reached for this secondary end point according to results presented during the ASCO Plenary Series: March 2022 Session.

The results are consistent with those of the primary analysis as the study previously met its primary end point of progression-free survival. The combination of relatlimab and nivolumab continues to demonstrate benefit compared to nivolumab alone in patients with previously untreated metastatic or unresectable melanoma, according to findings from the RELATIVITY-047 study (NCT03470922).

READ THE ORIGINAL FULL ARTICLE